• Users Online: 133
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 2  |  Issue : 4  |  Page : 257-264

Glutamic acid decarboxylase auto-antibodies prevalence among patients with type 2 diabetes mellitus and their clinical characteristics in a sample of the Egyptian population


1 Department of Clinical and Chemical Pathology; Department of Internal Medicine, National Institute of Diabetes and Endocrinology, Cairo, Egypt
2 Department of Clinical and Chemical Pathology; Department of Internal Medicine, National Institute of Diabetes and Endocrinology, Cairo, Egypt

Correspondence Address:
Ayat I Ghanem
5 Amin El Rafeey Street, Dokki 12611
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JMISR.JMISR_49_19

Rights and Permissions

Background Patients with latent autoimmune diabetes in adults may develop early loss of β-cell mass. They are often misdiagnosed as having type 2 diabetes mellitus (T2DM). This is because latent autoimmune diabetes in adults condition does share characteristics of both type 1 and T2DM. Aim To estimate the prevalence of unrecognized cases with glutamic acid decarboxylase auto-antibodies (GADA) among patients with T2DM in a sample of the Egyptian population, describing their clinical and laboratory features, and investigating the relationship with chronic complications of diabetes. Settings and design A total of 1515 Egyptian patients previously diagnosed as having T2DM were divided into two groups based on presence versus absence of GADA. Demographic and clinical characteristics were compared. Patients and methods Patients were selectively admitted according to clear criteria after informed consent and approval of the Ethics Committee. Patients underwent comprehensive history taking and examination. Laboratory investigations included blood chemistry, C-peptide, and GADA. Statistical analysis Data were analyzed using SPSS. Results Overall, 12.8% of patients with T2DM were GADA positive, showing lower C-peptide levels (P < 0.001). GADA-positive patients with T2DM demonstrated a positive correlation of GADA levels with central obesity (r = 0.175; P = 0.015) and systolic blood pressure (r = 0.171; P = 0.018). Moreover, a negative correlation with cardiovascular diseases (r=−0.0175; P = 0.015) was observed. Conclusion Prevalence of GADA among patients with T2DM in the analyzed sample was 12.8%, which agrees with the findings in other populations. These patients had lower C-peptide levels. GADA measurements are recommended in patients with T2DM with low C-peptide levels, especially in newly diagnosed patients, to help identify positive cases and initiate early insulin treatment to help preserve β-cell function and decrease the risk of long-term complications.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed160    
    Printed26    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal